Literature DB >> 3208806

Prognostic factors in stage I and II high and intermediate grade non-Hodgkin's lymphoma.

J F Mackintosh1, R A Cowan, M Jones, M Harris, D P Deakin, D Crowther.   

Abstract

Between 1975 and 1986, the Manchester Lymphoma Group treated 127 patients with localized (Stages I/II) high and intermediate grade non-Hodgkin's lymphoma (NHL) on one of three protocols of combined involved field radiotherapy and chemotherapy. The study included patients with widespread bulky abdominal disease providing there was no apparent spread outside the abdomen and the liver was not involved with metastatic disease. The median duration of follow-up was 70 months. The complete response rate was 86% and the overall 5-year survival was 70%. The 5-year relapse-free survival of the complete responders was 80%. Cox model multivariate analysis showed that bulk disease (greater than 5 cm), low serum albumin and gut involvement were the pretreatment factors associated with shorter survival. When remission status was included in the model the attainment of a complete response was the major determinant of long-term survival but bulk disease and gut involvement were still significant adverse predictors for survival. These factors need to be assessed when analysing results of therapy in NHL and in the design of future treatment strategies.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3208806     DOI: 10.1016/0277-5379(88)90054-5

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  6 in total

1.  Intraoperative radiation therapy for a patient with bulky disease of mesenteric non-Hodgkin's lymphoma.

Authors:  H Yamaue; H Tanimura; H Terasawa; Y Nakatani; T Tsunoda; M Tani; M Iwahashi
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

2.  Tumor Burden Assessed by the Maximum Standardized Uptake Value and Greatest Diameter on FDG-PET Predicts Prognosis in Untreated Diffuse Large B-cell Lymphoma.

Authors:  Xuan Canh Nguyen; Won Woo Lee; Amr Mohamed Amin; Jae Seon Eo; Soo-Mee Bang; Jong Seok Lee; Sang Eun Kim
Journal:  Nucl Med Mol Imaging       Date:  2010-02-26

Review 3.  Clinical aspects of early stage non-Hodgkin's lymphoma.

Authors:  G M Mead
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

4.  Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma.

Authors:  R A Cowan; M Jones; M Harris; W P Steward; J A Radford; J Wagstaff; D P Deakin; D Crowther
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

5.  Involved field radiotherapy or chemotherapy in the management of stage I nodal intermediate grade non-Hodgkin's lymphoma.

Authors:  G M Jeffery; G M Mead; J M Whitehouse; R D Ryall
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

6.  Prognostic factors in HIV-positive patients with non-Hodgkin lymphoma: a Peruvian experience.

Authors:  Luis Ernesto Cuellar; Andrea Anampa-Guzmán; Alexis Manuel Holguín; Juan Velarde; Diana Portillo-Alvarez; Marco Antonio Zuñiga-Ninaquispe; Esther Rosa Luna-Reyes; Jule Vásquez; Joanne Marie Jeter; Karen Marie Winkfield
Journal:  Infect Agent Cancer       Date:  2018-07-31       Impact factor: 2.965

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.